Date: 2013-12-17
Type of information: Development agreement
Compound: novel Anticalin®-based protein therapeutics, primarily focusing on ophthalmology
Company: Pieris (Germany) Stelis Biopharma (India)
Therapeutic area: Ophtalmological diseases
Type agreement: development
commercialisation
Action mechanism:
Disease:
Details: * On December 17, 2013, Stelis Biopharma, a subsidiary of Strides Arcolab Limited, focused on biotherapeutic drug development and bio-manufacturing, and Pieris AG, a next generation therapeutic protein R&D company, have announced the initiation of a long-term collaboration for clinical development and commercialization of multiple novel Anticalin®-based protein therapeutics worldwide, primarily focusing on ophthalmology. The alliance deploys the synergies of Pieris’ innovative drug discovery and early development capabilities with Stelis’ strong bio-manufacturing and clinical development expertise. Under the terms of the agreement, Pieris will advance each collaborative program through in vivo proof of concept, at which stage Stelis will be responsible for drug manufacturing and advancing the molecule through a first-in-human clinical study. Following positive clinical data, the parties will co-develop programs under a joint venture.
Financial terms:
Latest news:
